2025-04-13 - Analysis Report
## Recursion Pharmaceuticals Inc (RXRX) Stock Report

**0. Key Figures Summary:**

* **RXRX Cumulative Return:** -48.68%
* **VOO (S&P 500) Cumulative Return:** 11.44%
* **RXRX vs VOO Return Difference:** -60.1%
* **RXRX Closing Price:** $5.76
* **Market Risk Indicator (MRI):** 0.47 (High Risk)

**1. Performance Comparison & Alpha/Beta Analysis:**

Recursion Pharmaceuticals Inc (RXRX) is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics.

RXRX significantly underperformed the S&P 500 (VOO) over the analyzed period, lagging by 60.1%.  This places it in the 10.7th percentile of its historical relative performance against the S&P 500, based on a range of -70.7% to 28.3%.


The Alpha/Beta analysis shows consistently negative alpha values, suggesting underperformance relative to the market, coupled with a high beta (around 4.0), indicating high volatility and sensitivity to market movements.  The CAGR is low and inconsistent, reflecting the overall poor performance.  The high Maximum Drawdown (MDD) consistently above 70% highlights significant risk.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -10.0% | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -21.0% | 2.7 |
| 2023-2025  | 3.0% | 73.6% | -8.0% | 2.3 |


**2. Recent Price Movement:**

* **Closing Price:** $5.76
* **Previous Close:** $4.51
* **Daily Change:** +27.72% (Significant daily increase)
* **5-Day Moving Average:** $4.62
* **20-Day Moving Average:** $5.60
* **60-Day Moving Average:** $6.93

The recent price shows a significant one-day jump, surpassing both the 5-day and 20-day moving averages, but still below the 60-day average, suggesting potential short-term upward momentum but overall bearish trend.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.47 (High Risk) indicating considerable market volatility.
* **RSI:** 40.25 (Approaching oversold territory, but not decisively so)
* **PPO:** -0.088 (Negative, suggesting bearish momentum)
* **20-Day Relative Divergence Change:** -2.7% (Short-term bearish trend)
* **Expected Return:** -293.3% (This extremely negative figure warrants further investigation and should be treated with caution.  It is likely based on a specific model and assumptions that need to be verified.)

The significant daily price change (+27.72%) indicates a sharp upward movement.  However, the negative expected return and high MRI suggest considerable risk. The combination of RSI nearing oversold, a negative PPO, and a negative relative divergence reinforces a bearish outlook, despite the recent price jump.

**4. Recent Earnings Analysis:**

The company is consistently reporting negative EPS and low revenue, indicating significant financial challenges.  There's no clear trend of improvement, with minimal revenue growth and persistent losses.


| 날짜       | EPS     | 매출       |
|------------|---------|------------|
| 2024-11-06 | -0.34   | $0.03 B     |
| 2024-08-08 | -0.4    | $0.01 B     |
| 2024-05-09 | -0.39   | $0.01 B     |
| 2023-11-09 | -0.43   | $0.01 B     |
| 2024-11-06 | -0.43   | $0.01 B     |


**5. Financial Information:**

Revenue is low and fluctuating, while profit margins are highly erratic, swinging between substantial losses and positive but low margins.  ROE is consistently negative, indicating that the company is not generating returns on its equity.


**Revenue and Profitability:**

| Quarter     | Revenue   | Profit Margin |
|-------------|-----------|---------------|
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |
| 2024-03-31 | $0.01B    | 17.23%        |
| 2023-12-31 | $0.01B    | 6.99%         |


**Capital and Profitability:**

| Quarter     | Equity    | ROE          |
|-------------|-----------|--------------|
| 2024-12-31 | $1.03B    | -17.29%       |
| 2024-09-30 | $0.52B    | -18.27%       |
| 2024-06-30 | $0.58B    | -16.69%       |
| 2024-03-31 | $0.40B    | -22.78%       |
| 2023-12-31 | $0.46B    | -20.07%       |



**6. Overall Analysis:**

RXRX presents a highly risky investment.  The company is significantly underperforming the market, exhibiting high volatility, and consistently reporting negative earnings and ROE. While the recent price surge is noteworthy, it's likely a short-term event, not indicative of a long-term turnaround. The extremely negative expected return (-293.3%) suggests a highly bearish outlook and should be treated with extreme caution.  The financial statements reveal a company struggling with profitability and revenue generation.  Before considering any investment, a thorough due diligence is critical, including a careful review of the assumptions underlying the expected return calculation.  Currently, the data strongly suggests a high-risk, potentially high-loss scenario.
